Compass Therapeutics, Inc. (NASDAQ:CMPX) Stock Has Average Target Price of $10.21

Key Points

• Analysts maintain a Moderate Buy consensus on Compass Therapeutics, with 12 buys, three holds, one sell and one strong buy among 17 analysts. The average 12-month price target is $10.21, well above the stock’s recent $0.86 price.
• Institutional investors own 68.43% of CMPX, with several hedge funds increasing or initiating positions during the second quarter, including a substantial stake increase by Squarepoint Ops.
• The stock remains near its one-year low of $0.83 after falling well below its 50-day and 200-day moving averages. Compass also missed its latest quarterly EPS estimate, reporting a loss of $0.13 per share versus the expected $0.11 loss.

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seventeen analysts that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, twelve have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $10.21.

Several research firms recently issued reports on CMPX. Guggenheim cut their target price on Compass Therapeutics to $4.00 and set a "buy" rating for the company in a research report on Wednesday, September 23rd. Wall Street Zen lowered shares of Compass Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Compass Therapeutics in a report on Friday, July 17th. Piper Sandler increased their price objective on shares of Compass Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a report on Friday, August 7th. Finally, Wedbush set a $4.00 price objective on Compass Therapeutics in a research report on Wednesday, September 23rd.

Institutional Trading of Compass Therapeutics

Several hedge funds have recently modified their holdings of the company. Sequoia Financial Advisors LLC raised its stake in Compass Therapeutics by 189.5% during the second quarter. Sequoia Financial Advisors LLC now owns 44,980 shares of the company's stock valued at $99,000 after purchasing an additional 29,445 shares in the last quarter. WINTON GROUP Ltd bought a new position in Compass Therapeutics during the second quarter valued at $55,000. Squarepoint Ops LLC grew its stake in shares of Compass Therapeutics by 1,906.9% in the 2nd quarter. Squarepoint Ops LLC now owns 1,007,507 shares of the company's stock worth $2,206,000 after buying an additional 957,305 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Compass Therapeutics in the 2nd quarter worth about $71,000. Finally, HB Wealth Management LLC purchased a new stake in shares of Compass Therapeutics during the 2nd quarter valued at about $29,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Price Performance

Shares of CMPX stock opened at $0.86 on Friday. Compass Therapeutics has a one year low of $0.83 and a one year high of $6.88. The company's fifty day moving average price is $1.98 and its 200-day moving average price is $2.73. The company has a market capitalization of $154.28 million, a price-to-earnings ratio of -2.14 and a beta of 1.02.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02). Equities research analysts expect that Compass Therapeutics will post -0.47 earnings per share for the current fiscal year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based immunotherapies for the treatment of cancer. The company's research is centered on therapies designed to activate and direct the immune system against tumor cells, with the goal of improving anti-tumor responses and addressing limitations associated with existing cancer treatments.

Compass Therapeutics' pipeline has included CTX-471, an investigational agonist antibody targeting CD137, also known as 4-1BB.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.